Can dendritic cells improve whole cancer cell vaccines based on immunogenically killed cancer cells?

OncoImmunology

Volumn 4, Issue 12, 2015, Pages

  Cicchelero, Laetitia ^a   Denies, Sofie ^a   Devriendt, Bert ^a   de Rooster, Hilde ^a   Sanders, Niek N ^a  

^a GHENT UNIVERSITY   (Belgium)

Author keywords

co incubation; fusion; immunogenic cell death; whole cancer cell vaccine

Indexed keywords

CANCER VACCINE; CD40 ANTIGEN; CD86 ANTIGEN; DENDRITIC CELL VACCINE; GAMMA INTERFERON; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 12; INTERLEUKIN 4; LUCIFERASE; MITOXANTRONE; UNCLASSIFIED DRUG; WHOLE CANCER CELL VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW DERIVED DENDRITIC CELL; BREAST CANCER CELL LINE; BREAST CARCINOMA; CANCER IMMUNIZATION; CELL DEATH; CELL FUSION; CELL KILLING; CELL MATURATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENIC CANCER CELL DEATH; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; SPLEEN CELL; TH1 CELL; TH2 CELL;

EID: 84944552554     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1048413     Document Type: Article

References (54)

1. M.P.Brown, N.Burdett. Targeted therapies, aspects of pharmaceutical and oncological management. Cancer Forum 2013; 37:70-80
2. M.O.Lasaro, H.C.Ertl. Targeting inhibitory pathways in cancer immunotherapy. CurrOpinImmunol 2010; 22:385-90
3. J.Schlom, J.L.Gulley, P.M.Arlen. Paradigm shifts in cancer vaccine therapy. Exp Biol Med(Maywood) 2008; 233:522-34
4. J.B.Vermorken, A.M.Claessen, T.H.van, H.E.Gall, R.Ezinga, S.Meijer, R.J.Scheper, C.J.Meijer, E.Bloemena, J.H.Ransom, et al. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet 1999; 353:345-50; PMID:9950438; http://dx.doi.org/10.1016/S0140-6736(98)07186-4
5. L.E.Raez, P.A.Cassileth, J.J.Schlesselman, K.Sridhar, S.Padmanabhan, E.Z.Fisher, P.A.Baldie, E.R.Podack. Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer. J Clin Oncol 2004; 22:2800-7 ; http://dx.doi.org/10.1200/JCO.2004.10.197
6. L.M.Finocchiaro, G.L.Fiszman, A.L.Karara, G.C.Glikin. Suicide gene and cytokines combined nonviral gene therapy for spontaneous canine melanoma. Cancer Gene Ther 2008; 15:165-72; PMID:18219342; http://dx.doi.org/10.1038/sj.cgt.7701096
7. G.S.Hogge, J.K.Burkholder, J.Culp, M.R.Albertini, R.R.Dubielzig, E.T.Keller, N.S.Yang, E.G.MacEwen. Development of human granulocyte-macrophage colony-stimulating factor-transfected tumor cell vaccines for the treatment of spontaneous canine cancer. HumGene Ther 1998; 9:1851-61
8. P.J.Bergman, J.McKnight, A.Novosad, S.Charney, J.Farrelly, D.Craft, M.Wulderk, Y.Jeffers, M.Sadelain, A.E.Hohenhaus, et al. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. Clin Cancer Res 2003; 9:1284-90
9. K.Serhal, C.Baillou, N.Ghinea, P.Fontanges, F.P.Dupuy, F.M.Lemoine, R.Lacave. Characteristics of hybrid cells obtained by dendritic cell/tumour cell fusion in a T-47D breast cancer cell line model indicate their potential as anti-tumour vaccines. Int J Oncol 2007; 31:1357-65
10. C.L.Chiang, F.Benencia, G.Coukos. Whole tumor antigen vaccines. Semin Immunol 2010; 22:132-43
11. C.L.Chiang, A.R.Hagemann, R.Leskowitz, R.Mick, T.Garrabrant, B.J.Czerniecki, L.E.Kandalaft, D.J.Powell, Jr., G.Coukos. Day-4 myeloid dendritic cells pulsed with whole tumor lysate are highly immunogenic and elicit potent anti-tumor responses. PLoS One 2011; 6:e28732; http://dx.doi.org/10.1371/journal.pone.0028732
12. I.Mellman, G.Coukos, G.Dranoff. Cancer immunotherapy comes of age. Nature 2011; 480:480-9; PMID:22193102; http://dx.doi.org/10.1038/nature10673
13. B.M.Andersen, J.R.Ohlfest. Increasing the efficacy of tumor cell vaccines by enhancing cross priming. Cancer Lett 2012; 325:155-64; PMID:22809568; http://dx.doi.org/10.1016/j.canlet.2012.07.012
14. J.Copier, A.Dalgleish. Overview of tumor cell-based vaccines. Int Rev Immunol 2006; 25:297-319; PMID:17169778; http://dx.doi.org/10.1080/08830180600992472
15. J.Gong, S.Koido, S.K.Calderwood. Cell fusion: from hybridoma to dendritic cell-based vaccine. Expert Rev Vaccines 2008; 7:1055-68; PMID:18767954; http://dx.doi.org/10.1586/14760584.7.7.1055
16. E.Gilboa. DC-based cancer vaccines. J Clin Invest 2007; 117:1195-203; PMID:17476349
17. M.L.Bagarazzi, J.Yan, M.P.Morrow, X.Shen, R.L.Parker, J.C.Lee, M.Giffear, P.Pankhong, A.S.Khan, K.E.Broderick, et al. Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses. Sci Transl Med 2012; 4:155ra38; http://dx.doi.org/10.1126/scitranslmed.3004414
18. T.J.Fry, J.L.Shand, M.Milliron, S.K.Tasian, C.L.Mackall. Antigen loading of DCs with irradiated apoptotic tumor cells induces improved anti-tumor immunity compared to other approaches. Cancer Immunol Immunother 2009; 58:1257-64
19. T.B.Kim, H.K.Park, J.H.Chang, I.H.Choi, K.H.Kim, S.J.Yoon, M.S.Lee, H.Jung, C.S.Kim. The establishment of dendritic cell-tumor fusion vaccines for hormone refractory prostate cancer cell. Korean J Urol 2010; 51:139-44
20. N.Inzkirweli, B.Guckel, C.Sohn, D.Wallwiener, G.Bastert, M.Lindner. Antigen loading of dendritic cells with apoptotic tumor cell-preparations is superior to that using necrotic cells or tumor lysates. Anticancer Res 2007; 27:2121-9; PMID:17695495
21. D.V.Krysko, A.D.Garg, A.Kaczmarek, O.Krysko, P.Agostinis, P.Vandenabeele. Immunogenic cell death and DAMPs in cancer therapy. NatRevCancer 2012; 12:860-75
22. O.Kepp, A.Tesniere, F.Schlemmer, M.Michaud, L.Senovilla, L.Zitvogel, G.Kroemer. Immunogenic cell death modalities and their impact on cancer treatment. Apoptosis 2009; 14:364-75; PMID:19145485; http://dx.doi.org/10.1007/s10495-008-0303-9
23. A.Tesniere, T.Panaretakis, O.Kepp, L.Apetoh, F.Ghiringhelli, L.Zitvogel, G.Kroemer. Molecular characteristics of immunogenic cancer cell death. Cell Death Differ 2008; 15:3-12.
24. L.Zitvogel, G.Kroemer. Introduction: the immune response against dying cells. Curr Opin Immunol 2008; 20:501-3; PMID:18657612
25. M.R.Posner, L.A.Cavacini, M.P.Upton, K.C.Tillman, E.R.Gornstein, C.M.Norris, Jr. Surface membrane-expressed CD40 is present on tumor cells from squamous cell cancer of the head and neck in vitro and in vivo and regulates cell growth in tumor cell lines. Clin Cancer Res 1999; 5:2261-70; PMID:10473114
26. J.Galea-Lauri, D.Darling, G.Mufti, P.Harrison, F.Farzaneh. Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell-leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination. Cancer Immunol Immunother 2002; 51:299-310; PMID:12111118
27. J.Y.Kao, Y.Gong, C.M.Chen, Q.D.Zheng, J.J.Chen. Tumor-derived TGF-β reduces the efficacy of dendritic cell/tumor fusion vaccine. J Immunol 2003; 170:3806-11; PMID:12646647
28. N.Casares, M.O.Pequignot, A.Tesniere, F.Ghiringhelli, S.Roux, N.Chaput, E.Schmitt, A.Hamai, S.Hervas-Stubbs, M.Obeid, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 2005; 202:1691-701; PMID:16365148
29. E.B.Golden, I.Pellicciotta, S.Demaria, M.H.Barcellos-Hoff, S.C.Formenti. The convergence of radiation and immunogenic cell death signaling pathways. Front Oncol 2012; 2:88; PMID:22891162
30. A.Ribas, L.H.Butterfield, J.A.Glaspy, J.S.Economou. Current developments in cancer vaccines and cellular immunotherapy. J Clin Oncol 2003; 21:2415-32; PMID:12805342
31. S.Kreis, D.Philippidou, C.Margue, I.Behrmann. IL-24: a classic cytokine and/or a potential cure for cancer? J Cell Mol Med 2008; 12:2505-10; PMID:18505472
32. F.Balkwill, A.Mantovani. Inflammation and cancer: back to Virchow? Lancet 2001; 357:539-45; PMID:11229684
33. S.Schreck, D.Friebel, M.Buettner, L.Distel, G.Grabenbauer, L.S.Young, G.Niedobitek. Prognostic impact of tumour-infiltrating Th2 and regulatory T cells in classical Hodgkin lymphoma. Hematol Oncol 2009; 27:31-9; PMID:18924115
34. D.G.Lim, B.K.Bieganowska, G.J.Freeman, D.A.Hafler. Examination of CD8+ T cell function in humans using MHC class I tetramers: similar cytotoxicity but variable proliferation and cytokine production among different clonal CD8+ T cells specific to a single viral epitope. J Immunol 2000; 165:6214-20; PMID:11086055
35. N.Bercovici, N.Haicheur, S.Massicard, F.Vernel-Pauillac, O.Adotevi, D.Landais, I.Gorin, C.Robert, H.M.Prince, J.J.Grob, et al. Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients. J Immunother 2008; 31:101-12; PMID:18157017
36. T.Hayashi, H.Tanaka, J.Tanaka, R.Wang, B.J.Averbook, P.A.Cohen, S.Shu. Immunogenicity and therapeutic efficacy of dendritic-tumor hybrid cells generated by electrofusion. Clin Immunol 2002; 104:14-20; PMID:12139943
37. W.T.Lee, K.Shimizu, H.Kuriyama, H.Tanaka, J.Kjaergaard, S.Shu. Tumor-dendritic cell fusion as a basis for cancer immunotherapy. Otolaryngol Head Neck Surg 2005; 132:755-64; PMID:15886631
38. Y.C.Wei, R.P.Sticca, J.Li, L.M.Holmes, K.E.Burgin, S.Jakubchak, H.Bouton-Verville, J.Williamson, K.Meyer, L.Evans, et al. Combined treatment of dendritoma vaccine and low-dose interleukin-2 in stage IV renal cell carcinoma patients induced clinical response: A pilot study. Oncol Rep 2007; 18:665-71; PMID:17671717
39. H.Tamai, S.Watanabe, R.Zheng, K.Deguchi, P.A.Cohen, G.K.Koski, S.Shu. Effective treatment of spontaneous metastases derived from a poorly immunogenic murine mammary carcinoma by combined dendritic-tumor hybrid vaccination and adoptive transfer of sensitized T cells. Clin Immunol 2008; 127:66-77; PMID:18262845
40. E.I.Cho, C.Tan, G.K.Koski, P.A.Cohen, S.Shu, W.T.Lee. Toll-like receptor agonists as third signals for dendritic cell-tumor fusion vaccines. Head Neck 2010; 32:700-7; PMID:19908319
41. J.Rosenblatt, B.Glotzbecker, H.Mills, B.Vasir, D.Tzachanis, J.D.Levine, R.M.Joyce, K.Wellenstein, W.Keefe, M.Schickler, et al. PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine. J Immunother 2011; 34:409-18; PMID:21577144
42. B.Vasir, Z.Wu, K.Crawford, J.Rosenblatt, C.Zarwan, A.Bissonnette, D.Kufe, D.Avigan. Fusions of dendritic cells with breast carcinoma stimulate the expansion of regulatory T cells while concomitant exposure to IL-12, CpG oligodeoxynucleotides, and anti-CD3/CD28 promotes the expansion of activated tumor reactive cells. J Immunol 2008; 181:808-21; PMID:18566447
43. M.Branham-O'Connor, J.Li, H.S.Kotturi, X.Yu, T.E.Wagner, Y.Wei. Fusion induced reversal of dendritic cell maturation: an altered expression of inflammatory chemokine and chemokine receptors in dendritomas. Oncol Rep 2010; 23:545-50; PMID:20043120
44. M.A.Burchill, B.A.Tamburini, N.D.Pennock, J.T.White, J.S.Kurche, R.M.Kedl. T cell vaccinology: exploring the known unknowns. Vaccine 2013; 31:297-305; PMID:23137843; http://dx.doi.org/10.1016/j.vaccine.2012.10.096
45. B.A.Hurn, S.M.Chantler. Production of reagent antibodies. Methods Enzymol 1980; 70:104-42; PMID:6999294
46. K.Asano, A.Nabeyama, Y.Miyake, C.H.Qiu, A.Kurita, M.Tomura, O.Kanagawa, S.Fujii, M.Tanaka. CD169-positive macrophages dominate antitumor immunity by crosspresenting dead cell-associated antigens. Immunity 2011; 34:85-95; PMID:21194983; http://dx.doi.org/10.1016/j.immuni.2010.12.011
47. M.Y.Gerner, P.Torabi-Parizi, R.N.Germain. Strategically localized dendritic cells promote rapid T cell responses to lymph-borne particulate antigens. Immunity 2015; 42:172-85; PMID:25607462; http://dx.doi.org/10.1016/j.immuni.2014.12.024
48. A.Ewens, E.Mihich, M.J.Ehrke. Distant metastasis from subcutaneously grown E0771 medullary breast adenocarcinoma. Anticancer Res 2005; 25:3905-15; PMID:16312045
49. F.Xing, J.Wang, M.Hu, Y.Yu, G.Chen, J.Liu. Comparison of immature and mature bone marrow-derived dendritic cells by atomic force microscopy. Nanoscale Res Lett 2011; 6:455; PMID:21762525; http://dx.doi.org/10.1186/1556-276X-6-455
50. D.A.Mitchell, K.A.Batich, M.D.Gunn, M.N.Huang, L.Sanchez-Perez, S.K.Nair, K.L.Congdon, E.A.Reap, G.E.Archer, A.Desjardins, et al. Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature 2015; 519:366-9; PMID:25762141; http://dx.doi.org/10.1038/nature14320.
51. I.K.Van, J.Bethuyne, S.Cool, F.Impens, D.Ruano-Gallego, W.O.De, B.Vanloo, T.M.Van, K.Lambein, C.Boucherie, et al. A nanobody targeting the F-actin capping protein CapG restrains breast cancer metastasis. Breast Cancer Res 2013; 15:R116; PMID:24330716; http://dx.doi.org/10.1186/bcr3585.
52. M.B.Lutz, N.Kukutsch, A.L.Ogilvie, S.Rossner, F.Koch, N.Romani, G.Schuler. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 1999; 223:77-92; PMID:10037236; http://dx.doi.org/10.1016/S0022-1759(98)00204-X
53. T.-F.K.Chien-Chun Pai, J.T.Simon T.-F.C.MaocTien-Fu Chuanga, L.Chen-SiLina, C.Rea-MinChu. Immunopathogenic behaviors of canine transmissible venereal tumor in dogs following an immunotherapy using dendritic/tumor cell hybrid. Vet Immunol Immunopathol 2011; 139:187-99; PMID:21051091; http://dx.doi.org/10.1016/j.vetimm.2010.10.013
54. S.Denies, L.Cicchelero, I.Van Audenhove, N.N.Sanders. Combination of interleukin-12 gene therapy, metronomic cyclophosphamide and DNA cancer vaccination directs all arms of the immune system towards tumor eradication. J Control Release 2014; 187:175-82; PMID:24887014; http://dx.doi.org/10.1016/j.jconrel.2014.05.045